IMMUNOCYTOCINS COMBINED THERAPY Russian patent published in 2017 - IPC A61K38/19 A61K38/20 A61K47/68 

FIELD: pharmacology.

SUBSTANCE: method for skin tumor treatment by TNF immunoconjugate single dose injectionα and IL-2 immunoconjugate single dose to tumor localization site, at that, injectable administration of TNF immunoconjugateα and IL-2 immunoconjugate is carried out simultaneously. TNF immunoconjugateα contains TNFα, bound to an antibody molecule that binds to the additional ED-B domain of the B-FN fibronectin splice isoform. The IL-2 immunoconjugate comprises IL-2, bound to an antibody molecule that binds to the additional ED-B domain of the B-FN fibronectin splice isoform. The invention also relates to compositions for skin tumor treatment comprising the said TNF immunoconjugateα and/or the said IL-2 immunoconjugate.

EFFECT: invention provides for stimulation of complete destruction of large subcutaneous tumors with a single local administration of a combination of TNF immunoconjugateα and IL-2 immunoconjugate.

42 cl, 4 dwg